HMG-CoA reductase / Calcium channel

Class

Statin + calcium-channel-blocker fixed-dose combination

This fixed-dose combination pairs two drugs that address different, additive risk factors for cardiovascular disease: an inhibitor of HMG-CoA reductase (a statin) and a calcium channel blocker (CCB). HMG-CoA reductase is the rate-limiting enzyme in the liver's cholesterol-synthesis pathway; blocking it lowers hepatic cholesterol production, which prompts liver cells to import more cholesterol from the blood and thereby reduces circulating LDL cholesterol, a principal driver of atherosclerotic plaque formation. Calcium channel blockers act on a different physiological node, interfering with calcium entry into vascular smooth muscle cells, causing these vessels to relax and lowering blood pressure. Because elevated LDL cholesterol and hypertension are independent, commonly coexisting risk factors for heart attack and stroke, combining both mechanisms in one tablet allows simultaneous management of lipid levels and blood pressure. This approach is used broadly in cardiovascular risk reduction, particularly for patients who require long-term therapy for both conditions, where a single combined formulation can also simplify treatment regimens. The two components act through unrelated pathways, so their effects are considered complementary rather than mechanistically overlapping, each addressing a distinct contributor to vascular disease.